BARR/NOVOPHARM APPEAL OF AZT PATENT DECISION
BARR/NOVOPHARM APPEAL OF AZT PATENT DECISION appears to hinge on whether the D.C. circuit court finds that a New Bern, N.C. lower federal court inappropriately halted a jury trial prior to relevant testimony regarding a mouse retroviral test's ability to predict activity of Burroughs Wellcome's Retrovir (zidovudine) in humans. Oral arguments were heard in the case before D.C. federal circuit court judges Alan Lourie, Robert Mayer and Alvin Scholl on May 2. A ruling is not expected until mid-summer.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth